Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy of Darbepoetin alfa in Anemia Developed during Chemotherapy for Lung Cancer

폐암 환자에서 항암화학치료 중 발생한 빈혈에 대한 Darbepoetin alfa의 효과

  • Ban, Hee-Jung (Department of Internal Medicine, Chonnam National University Medical School) ;
  • Chi, Su-Young (Department of Internal Medicine, Chonnam National University Medical School) ;
  • Park, Cheol-Kyu (Department of Internal Medicine, Chonnam National University Medical School) ;
  • Kim, Eun-Young (Department of Internal Medicine, Chonnam National University Medical School) ;
  • Kim, Yoon-Hee (Department of Internal Medicine, Chonnam National University Medical School) ;
  • Kim, Kyu-Sik (Department of Internal Medicine, Chonnam National University Medical School) ;
  • Ju, Jin-Young (Department of Internal Medicine, Chonnam National University Medical School) ;
  • Kwon, Yong-Soo (Department of Internal Medicine, Chonnam National University Medical School) ;
  • Oh, In-Jae (Department of Internal Medicine, Chonnam National University Medical School) ;
  • Kim, Yu-Il (Department of Internal Medicine, Chonnam National University Medical School) ;
  • Lim, Sung-Chul (Department of Internal Medicine, Chonnam National University Medical School) ;
  • Kim, Young-Chul (Department of Internal Medicine, Chonnam National University Medical School)
  • 반희정 (전남대학교 의과대학 내과학교실) ;
  • 지수영 (전남대학교 의과대학 내과학교실) ;
  • 박철규 (전남대학교 의과대학 내과학교실) ;
  • 김은영 (전남대학교 의과대학 내과학교실) ;
  • 김윤희 (전남대학교 의과대학 내과학교실) ;
  • 김규식 (전남대학교 의과대학 내과학교실) ;
  • 주진영 (전남대학교 의과대학 내과학교실) ;
  • 권용수 (전남대학교 의과대학 내과학교실) ;
  • 오인재 (전남대학교 의과대학 내과학교실) ;
  • 김유일 (전남대학교 의과대학 내과학교실) ;
  • 임성철 (전남대학교 의과대학 내과학교실) ;
  • 김영철 (전남대학교 의과대학 내과학교실)
  • Received : 2008.10.05
  • Accepted : 2009.02.03
  • Published : 2009.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Anemia is quite common in lung cancer patients and known to decrease the quality of life. Darbepoetin alfa is an erythropoiesis-stimulating protein approved for administration to cancer patients. This study examined the efficacy and safety of darbepoetin alfa in lung cancer patients with a hemoglobin concentration <10 g/dl during chemotherapy. Methods: Lung cancer patients (n=178) received darbepoetin alfa at doses of 1.91 ${\mu}g/kg$ per week until the hemoglobin concentration increased to >10 g/dl. The efficacy and safety were measured by comparing the hemoglobin concentration and assessing the adverse events. Results: After chemotherapy, the hemoglobin concentration decreased to 9.03${\pm}$0.64 g/dl. With the darbepoetin alfa treatment, the hemoglobin concentration increased to 10.09${\pm}$1.17 g/dl after 4 weeks reaching a peak hemoglobin concentration of 10.45${\pm}$1.18 g/dl. The changes in hemoglobin after 4 and 8 weeks with treatment were 1.08${\pm}$1.24 g/dl and 1.38${\pm}$1.59 g/dl (p<0.01). At least a 1 g/dl or more increase in hemoglobin was observed in 62.4% of patients. There were no serious adverse effects except for some mild reactions. Conclusion: Darbepoetin alfa administered to lung cancer patients appears to be an effective, well-tolerated treatment for chemotherapy induced anemia.

연구배경: 빈혈은 폐암 환자의 항암 치료중 발생하여 삶의 질을 떨어뜨리는 원인이 된다. 최근 사용 되는 darbepoetin alfa는 적혈구 생성 촉진 인자로 사용되고 있어 이의 효과와 부작용을 알아보고자 하였다. 방 법: 2004년 9월부터 2007년 3월까지 화순전남대학교 병원을 내원한 환자 중에서 소세포 혹은 비소세포 폐암을 진단받고 항암 화학 치료를 적어도 1개월 이상 받은 환자들 중에서 혈색소 수치 10 g/dl 미만의 빈혈이 발생한 환자들 중 darbepoetin alfa를 투여 받은 환자를 대상으로 후향적으로 분석하였다. 결 과: 항암 화학 치료 후 혈색소는 9.03${\pm}$0.64 g/dl로 감소하였고, darbepoetin alfa를 처치 후 혈색소 1 g/dl 이상의 증가를 보였던 환자는 62.4%였으며 최고치 10.45${\pm}$1.18 g/dl, 4주째 10.09${\pm}$1.17 g/dl로 관찰되었다. 경증 부작용이 일부에서 관찰되었나 모두 호전되었다. 결 론: darbepoetin alfa는 항암 치료와 연관된 빈혈의 치료에 효과적이며 부작용이 심하지 않아 보조 치료제로 사용될 수 있겠다.

Keywords

References

  1. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-34 https://doi.org/10.1093/jnci/91.19.1616
  2. Scagliotti GV, Novello S. Role of erythropoietin in the treatment of lung cancer associated anaemia. Lung Cancer 2001;34 Suppl 4:S91-4 https://doi.org/10.1016/S0169-5002(01)00355-5
  3. Lyman GH, Berndt ER, Kallich JD, Erder MH, Crown WH, Long SR, et al. The economic burden of anemia in cancer patients receiving chemotherapy. Value Health 2005;8:149-56 https://doi.org/10.1111/j.1524-4733.2005.03089.x
  4. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. Second of two parts--blood conservation. N Engl J Med 1999;340:525-33 https://doi.org/10.1056/NEJM199902183400706
  5. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of onceweekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-82 https://doi.org/10.1200/JCO.2001.19.11.2875
  6. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412-25 https://doi.org/10.1200/JCO.1998.16.10.3412
  7. Cella D, Zagari MJ, Vandoros C, Gagnon DD, Hurtz HJ, Nortier JW. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 2003;21:366-73 https://doi.org/10.1200/JCO.2003.02.136
  8. Cella D, Kallich J, McDermott A, Xu X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 2004;15:979-86 https://doi.org/10.1093/annonc/mdh235
  9. Berndt E, Kallich J, McDermott A, Xu X, Lee H, Glaspy J. Reductions in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy. Pharmacoeconomics 2005; 23:505-14 https://doi.org/10.2165/00019053-200523050-00009
  10. Patton J, Reeves T, Wallace J. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy- induced anemia treated in clinical practice. Oncologist 2004;9:451-8 https://doi.org/10.1634/theoncologist.9-4-451
  11. Waltzman R, Croot C, Justice GR, Fesen MR, Charu V, Williams D. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist 2005;10:642-50 https://doi.org/10.1634/theoncologist.10-8-642
  12. Information for Healthcare Professionals [Internet]. Silver Spring: U.S. Food and Drug Administration/ Center for Drug Evaluation and Research; c2007. Erythropoiesis Stimulating Agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoe tin alfa)]; 2007 Feb 16 [cited 2007 Mar 21]. Available from: http://www.fda.gov/cder/drug/InfoSheets/HCP/ RHE2007HCP.htm
  13. Senecal FM, Yee L, Gabrail N, Charu V, Tomita D, Rossi G, et al. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly. Clin Breast Cancer 2005; 6:446-54 https://doi.org/10.3816/CBC.2005.n.050
  14. Aranesp (darbepoetin alfa) [package insert]. Thousand oaks, CA: Amgen Inc.; March 2008
  15. Procrit (epoetin alfa) [package insert]. Raritan, NJ: OrthoBiotech. L.P.; March 2008
  16. Lastiri JM, Specterman SR, Rendo P, Pallotta MG, Varela MS, Goldstein S. Predictive response variables to recombinant human erythropoietin treatment in patients with anemia and cancer. Medicina (B Aires) 2002;62:41-7
  17. Rodgers GM. Clinical practice guidelines in oncology: cancer and treatment-related anemia [Internet]. Fort Washington: National Comprehensive Cancer Network; 2005 [cited 2005 Dec 10]. Available from: http://www. nccn.org/professionals/physician_gls/f_guidelines.asp